home / stock / nby / nby news


NBY News and Press, NovaBay Pharmaceuticals Inc. From 10/11/23

Stock Information

Company Name: NovaBay Pharmaceuticals Inc.
Stock Symbol: NBY
Market: NYSE
Website: novabay.com

Menu

NBY NBY Quote NBY Short NBY News NBY Articles NBY Message Board
Get NBY Alerts

News, Short Squeeze, Breakout and More Instantly...

NBY - NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of...

NBY - NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8 th Annual Dawson Ja...

NBY - Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...

NBY - NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’...

NBY - NovaBay stock soars 86% on optic allograft product deal

2023-09-11 09:49:45 ET More on NovaBay Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay NovaBay Pharmaceuticals, Inc. ( NBY ) Q2 2023 Earnings Call Transcript For further details...

NBY - NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the...

NBY - NioBay commences its 2023 drilling campaign at the Crevier project

MONTRÉAL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- NioBay Metals inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the start of a drilling campaign on the Crevier Property, which is owned by Les Minéraux Crevier Inc, of which NioBay...

NBY - NovaBay GAAP EPS of -$1.27 misses by $0.71, revenue of $4.61M beats by $0.94M

2023-08-10 16:10:51 ET NovaBay press release ( NYSE: NBY ): Q2 GAAP EPS of -$1.27 misses by $0.71 . Revenue of $4.61M (+28.1% Y/Y) beats by $0.94M . For further details see: NovaBay GAAP EPS of -$1.27 misses by $0.71, revenue of $4.61M beats by $0.94M

NBY - NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results

Net product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high Sales and marketing expenses reduced by 16% through optimized digital marketing programs Operating loss decreased by 37% year-over-ye...

NBY - NovaBay Q2 2023 Earnings Preview

2023-08-09 17:35:09 ET NovaBay ( NYSE: NBY ) is scheduled to announce Q2 earnings results on Thursday, August 10th, after market close. The consensus EPS Estimate is -$0.56 and the consensus Revenue Estimate is $3.67M (+20.7% Y/Y). Over the last 3 months, EPS estimates...

Previous 10 Next 10